KR20210034621A - 알츠하이머병 치료를 위한 릴루졸 전구약물의 용도 - Google Patents

알츠하이머병 치료를 위한 릴루졸 전구약물의 용도 Download PDF

Info

Publication number
KR20210034621A
KR20210034621A KR1020217004639A KR20217004639A KR20210034621A KR 20210034621 A KR20210034621 A KR 20210034621A KR 1020217004639 A KR1020217004639 A KR 1020217004639A KR 20217004639 A KR20217004639 A KR 20217004639A KR 20210034621 A KR20210034621 A KR 20210034621A
Authority
KR
South Korea
Prior art keywords
patient
riluzole
administered
prodrug
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217004639A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
로버트 버만
이르판 큐레쉬
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20210034621A publication Critical patent/KR20210034621A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217004639A 2018-07-22 2019-07-20 알츠하이머병 치료를 위한 릴루졸 전구약물의 용도 Ceased KR20210034621A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
US62/701,814 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20210034621A true KR20210034621A (ko) 2021-03-30

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004639A Ceased KR20210034621A (ko) 2018-07-22 2019-07-20 알츠하이머병 치료를 위한 릴루졸 전구약물의 용도

Country Status (14)

Country Link
US (1) US12161633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530543A (cg-RX-API-DMAC7.html)
KR (1) KR20210034621A (cg-RX-API-DMAC7.html)
CN (1) CN112469408A (cg-RX-API-DMAC7.html)
AU (1) AU2019310013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107215A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190308A1 (cg-RX-API-DMAC7.html)
IL (1) IL280177B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000515A (cg-RX-API-DMAC7.html)
PH (1) PH12021550043A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100385YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US10751345B2 (en) * 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Also Published As

Publication number Publication date
AU2019310013B2 (en) 2025-01-02
WO2020023324A1 (en) 2020-01-30
MX2021000515A (es) 2021-06-08
SG11202100385YA (en) 2021-02-25
IL280177A (en) 2021-03-01
IL280177B1 (en) 2024-09-01
CA3107215A1 (en) 2020-01-30
JP2021530543A (ja) 2021-11-11
EP3823616A1 (en) 2021-05-26
EP3823616A4 (en) 2022-05-04
NZ772009A (en) 2026-02-27
BR112021000768A2 (pt) 2021-05-11
AU2019310013A1 (en) 2021-02-11
PH12021550043A1 (en) 2021-09-20
US12161633B2 (en) 2024-12-10
CN112469408A (zh) 2021-03-09
MX2024010655A (es) 2024-09-11
IL280177B2 (en) 2025-01-01
EA202190308A1 (ru) 2021-05-19
US20210290599A1 (en) 2021-09-23
JP2025093952A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
US12161633B2 (en) Use of riluzole prodrugs to treat alzheimer's disease
Reid et al. A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence
US20100178362A1 (en) Chromium complexes for improvement of memory and cognitive function
Yang et al. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone
CN105832733A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
KR20200103658A (ko) 실조증을 치료하기 위한 릴루졸 전구약물의 용도
US20240082340A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
JP2024524679A (ja) アルツハイマー病の処置方法
Wang et al. Exploratory study on the safety and effectiveness of Yizhi Qingxin Decoction (capsules) in the treatment of hypertension in the elderly with mild cognitive impairment (deficiency of kidney essence syndrome)
US12201618B2 (en) Use of riluzole prodrugs to treat Alzheimer's disease
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
Omar et al. Severe hyponatremia as poor prognostic factor in childhood neurologic diseases
US20040092589A1 (en) Use of retinoic acid for treatment of autism
EA049330B1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
Kim et al. Efficacy and safety of oral SOCG in treatment of major depressive disorder: A protocol for a phase II, randomized, double-blind, placebo controlled, parallel-groups, dose finding exploratory study
Schapira Parkinson's disease
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
Forcadell Ferré et al. Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults
Ramos-Quiroga et al. Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults: JA Ramos-Quiroga et al.
Khatri et al. New-onset functional dyspepsia after COVID-19
JP2026506974A (ja) シャルコー・マリー・トゥース病を処置するための組成物及び方法
EP4536238A1 (en) Treatment of binge eating disorder using psychedelics
Wilson et al. Effects of marijuana on brain: Function and structure
US20050032896A1 (en) Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
Gracious et al. Child and Adolescent Program of the 42nd Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 10–13, 2002

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)